217 related articles for article (PubMed ID: 16631805)
1. Sulfonylureas and the risk of myocardial infarction.
Thisted H; Johnsen SP; Rungby J
Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
[TBL] [Abstract][Full Text] [Related]
2. Oral sulfonylureas and CV mortality.
Aronow WS
Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
[No Abstract] [Full Text] [Related]
3. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
Gonçalves JV; Caldeira J
Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
[TBL] [Abstract][Full Text] [Related]
4. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
5. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
[No Abstract] [Full Text] [Related]
6. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
Horsdal HT; Søndergaard F; Johnsen SP; Rungby J
Pharmacoepidemiol Drug Saf; 2011 Apr; 20(4):331-7. PubMed ID: 21442682
[TBL] [Abstract][Full Text] [Related]
7. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Mühlhauser I; Sawicki PT; Berger M
Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
[No Abstract] [Full Text] [Related]
8. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
9. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
Hoshi M; Fujita S
Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
[No Abstract] [Full Text] [Related]
10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
11. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
[TBL] [Abstract][Full Text] [Related]
13. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and coronary heart disease.
Engler RL
N Engl J Med; 1998 Dec; 339(23):1715; author reply 1716. PubMed ID: 9867544
[No Abstract] [Full Text] [Related]
15. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
16. Does mortality risk vary among sulfonylureas?
Pantalone KM
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
[No Abstract] [Full Text] [Related]
17. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and coronary artery disease: time to stop taking the tablets.
Edwards RJ; Rakhit RD; Marber MS
Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
[No Abstract] [Full Text] [Related]
19. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease?
Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878
[No Abstract] [Full Text] [Related]
20. If not sulfonylureas, then what?
Leibovitch ER
Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
